NCT05123807招募中2 期
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
研究概览
简要总结
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
详细描述
PRIMARY OBJECTIVE:
The primary objective is to estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
SECONDARY OBJECTIVES:
- To estimate overall survival (OS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
- To evaluate toxicity and morbidity of secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
- To estimate quality of life after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
- To estimate what proportion of patients who preoperatively appear to be candidates for secondary cytoreductive surgery and HIPEC are found to have unresectable disease at time of surgical exploration
- To collect blood and tumor samples for biobanking to be used for exploratory endpoints
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer
- •Age ≥18 years
- •ECOG performance status ≤ 2
- •Prior to surgery, patients must have adequate organ and marrow function as defined below (within 30 days of registration):
- •absolute neutrophil count >1,500/mcL
- •platelets >100,000/mcL
- •total bilirubin ≤ 1.5 mg/dL
- •creatinine ≤ 1.5 mg/dL
- •AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal
- •Patients must be > 2 weeks from prior chemotherapy or radiation therapy, except for bevacizumab treatment which requires >6 weeks
- •Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)
排除标准
- •Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
- •Patients with mucinous tumors with pathologic confirmation of a non-gynecologic site of origin
- •Patients with known active CNS metastases
- •Patients with known hypersensitivity to any of the components of cisplatin
- •Patients with a prior or concurrent malignancy who natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Women who are pregnant or nursing women
- •Patients with peripheral neuropathy ≥ grade 2
- •History of allogenic transplant
- •History of prior HIPEC or intraperitoneal chemotherapy
- •Known bulky extra-abdominopelvic disease
- •Patients with hearing impairment/tinnitus ≥ grade 2
研究组 & 干预措施
Cytoreductive surgery
Other
干预措施: Cytoreductive surgery (Other)
结局指标
主要结局
To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
时间窗: through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStomach NeoplasmNCT03023436Nanfang Hospital, Southern Medical University220
已完成
不适用
Retrospective analysis of perioperative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), based on a surgical database of the University Hospital Dresden, referring to the years 2013-2020C16C18C20C22Malignant neoplasm of stomachMalignant neoplasm of colonMalignant neoplasm of rectumMalignant neoplasm of liver and intrahepatic bile ductsDRKS00028850niversitätsklinikum Carl Gustav Carus173
Unknown
3 期
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?Ovarian Epithelial Cancer RecurrentFallopian Tube CarcinomaPrimary Peritoneal CarcinomaNCT01611766Shanghai Gynecologic Oncology Group356
已完成
不适用
Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)Primary Peritoneal NeoplasmSecondary Peritoneal NeoplasmNCT01882920Regina Elena Cancer Institute80
已完成
不适用
Retrospective analysis of oncologic outcome and quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), based on a surgical database of the University Hospital Dresden, referring to the years 2013-2020C48Malignant neoplasm of retroperitoneum and peritoneumDRKS00028856niversitätsklinikum Carl Gustav Carus173